Pfizer Lung Cancer Drug Disappoints in Late-Stage Trials

Drug Industry Daily
A A
Pfizer’s lung cancer drug dacomitinib has failed in two Phase III clinical trials and analysts aren’t holding out much hope for results from a third Phase III study expected next year.

To View This Article:

Login

Subscribe To Drug Industry Daily